InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

- Current share price for OSL : $1.200

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$37 Share Option Vesting Conditions Met 23 Dec 2015 10:09AM $0.250 $1.200 risen by 380%
$37 Appendix 3F updated 23 Dec 2015 10:02AM $0.250 $1.200 risen by 380%
$37 OncoSil Medical appoints Charles Rowland President - USA 15 Dec 2015 9:48AM $0.155 $1.200 risen by 674.19%
$37 Notice of change of interests of substantial holder 14 Dec 2015 1:52PM $0.160 $1.200 risen by 650%
$37 US FDA Investigational Device Exemption submitted 14 Dec 2015 9:46AM $0.165 $1.200 risen by 627.27%
$37 ASIC 484 (Section C) 14 Dec 2015 9:12AM $0.165 $1.200 risen by 627.27%
$37 Appendix 3F 14 Dec 2015 9:11AM $0.165 $1.200 risen by 627.27%
$37 OncoSil Medical - Reciept of R&D Tax Incentive Refund 27 Nov 2015 10:04AM $0.175 $1.200 risen by 585.71%
$37 OncoSil Medical Appendix 3C 26 Nov 2015 4:27PM $0.175 $1.200 risen by 585.71%
$37 OncoSil Medical - results of the 2015 Annual General Meeting 26 Nov 2015 3:46PM $0.175 $1.200 risen by 585.71%
$37 OncoSil Medical AGM presentation November 26th 2015 26 Nov 2015 2:57PM $0.175 $1.200 risen by 585.71%
$37 OncoSil Medical Interview on CE Mark and Growth Plans 26 Nov 2015 8:50AM $0.170 $1.200 risen by 605.88%
$37 Notice of initial substantial shareholder 23 Nov 2015 4:00PM $0.165 $1.200 risen by 627.27%
$37 OncoSil Medical's CEO presents at ASX CEO session 17 Nov 2015 10:03AM $0.160 $1.200 risen by 650%
$37 OncoSil AGM Notice of Meeting 2015 10 Nov 2015 12:15PM $0.175 $1.200 risen by 585.71%
$37 OSL Voting Form 10 Nov 2015 12:06PM $0.175 $1.200 risen by 585.71%
$37 Release from escrow 9 Nov 2015 8:27AM $0.180 $1.200 risen by 566.67%
$37 Appendix 4C - Quarterly 29 Oct 2015 10:00AM $0.180 $1.200 risen by 566.67%
$37 OncoSil Medical appoints new CFO Tom Milicevic 22 Oct 2015 8:47AM $0.150 $1.200 risen by 700%
$37 OncoSil Medical CE Mark Update 12 Oct 2015 9:09AM $0.165 $1.200 risen by 627.27%
$37 OncoSil Medical cleansing notice and Appendix 3B 8 Oct 2015 10:51AM $0.170 $1.200 risen by 605.88%
$37 OncoSil strengthens management team 8 Oct 2015 9:15AM $0.155 $1.200 risen by 674.19%
$37 Van Leeuwenhoeck Institute initiates Research Coverage 1 Oct 2015 10:35AM $0.145 $1.200 risen by 727.59%
$37 Change of substantial shareholder interests 17 Sep 2015 8:27AM $0.140 $1.200 risen by 757.14%
$37 EU Fast Track Review for CE Mark confirmed 9 Sep 2015 8:27AM $0.096 $1.200 risen by 1,150%

726 - 750 of 794 results

Page 30 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.